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INTRODUCTION mice, and loss of expression of this gene has been shown in primary breast tumors. Furthermore, the
Breast cancer is a common neoplasm affecting human MDGI gene has been mapped to human chrowomen in the western world. The frequency of loss of mosome 1p32 -p35, a common region of deletion in heterozygosity (LOH) at different chromosomal loci in sporadic breast tumors. We have determined the gesporadic breast tumors suggests that a number of tunomic structure of the human MDGI gene from a cosmor suppressor genes are involved in the development mid clone mapping to chromosome 1p32 -p35 and have more finely mapped the MDGI gene relative to of the disease (Callahan et al., 1992) . One such gene chromosome 1p microsatellite markers. The gene may be the mammary-derived growth inhibitor (MDGI) covers approximately 8 kb of genomic DNA and is gene, which is located at 1p32-p35 (Hung et al., 1995) , divided into four exons. In an attempt to identify posa common region of loss in sporadic breast cancer (Borg sible inactivating mutations in the MDGI gene in hu- et al., 1992; Bieche et al., 1993 Bieche et al., , 1994 Munn et al., 1995) .
man breast cancer, we have sequenced all four exons
Based on the complete cDNA and protein homologies and their surrounding splice junctions in 30 sporadic between the mouse MDGI and fatty acid-binding probreast tumors. Ten of these tumors showed loss of tein 3-muscle and heart (FABP3) genes (Yang et al., heterozygosity (LOH) in the 1p32 -p35 region, with 5 1994; Treuner et al., 1994) , it is assumed that these are tumors showing LOH in the subregion containing the the same genes. Furthermore, two independent reports MDGI gene. No mutations were found in this analyhave mapped the human FABP3 and MDGI genes to sis. A polymorphism was identified in exon 2 in the the same region of chromosome 1 (1p32-p35) (Troxler constitutional DNA of 1/30 cases in this study, which Hung et al., 1995) , providing further eviresulted in the conversion of a lysine to an arginine dence that the human FABP3 and MDGI genes are residue at codon 53. This variant was present in the identical.
constitutional DNA of a further 3/26 women with spo-MDGI was first identified as a growth inhibitor in radic breast cancer and 2/90 control individuals (P lactating bovine mammary gland and was shown to Å 0.20). Despite experimental evidence that MDGI play a role in mammary gland differentiation (Böhmer et al., 1987; Spener et al., 1990; Grosse et al., 1991) . 1 To whom correspondence should be addressed at Division of Med-cases shown in Table 1 : D1S233, L-MYC, D1S197, D1S209, D1S438, tion (Yang et al., 1994) , and reduced tumor formation and D1S207 (Fig. 2) . The oligonucleotide primer sequences, allele in nude mice (compared to mock-transfected or unsizes, and order of markers along the chromosome are according to transfected controls) (Hung et al., 1995) . Immunostainthe Généthon genetic linkage map (Gyapay et al., 1994) . Genomic ing of sections of human breast tumors showed loss of DNA (100 ng) was amplified by PCR in 50 mM KCl, 10 mM Tris-HCl, pH 9.0, 1.0-2.0 mM MgCl (BRL) (depending on primer set), immunoreactive FABP3 protein in the neoplastic cells 0.2 mM dTTP, dCTP, and dGTP, 0.05 mM dATP, [a-35 S]dATP (Amercompared to its presence in adjacent normal epithelial sham) at 1 mCi/reaction, and 2 units of Taq DNA polymerase (BRL) cells (Hung et al., 1995) . Together these data suggest in a final volume of 25 ml. Thermocycling conditions consisted of 35 that MDGI/FABP3 is a candidate tumor suppressor cycles of 40 s at 94ЊC, 40 s at 55/58ЊC (depending on primer set), and gene involved in breast cancer. 40 s at 72ЊC, followed by one cycle of 3-min extension at 72ЊC. Reaction products were then diluted 1:2 with a stop buffer (90% for-We have previously isolated a cosmid clone conmamide, 10 mM EDTA, bromophenol blue, and xylene cylanol) and taining the entire MDGI gene (Hung et al., 1995) . In heated to 94ЊC for 10 min prior to loading on 6% polyacrylamide this report we describe the genomic structure of this sequencing gels. Gels were dried at 80ЊC and exposed to Kodak XARgene, including the number of exons, intron sizes, and 5 film. sequence and location of intron/exon boundaries. We scribed below) and the microsatellite markers (above) were amplified gene, we have sequenced the entire coding region of the in each of the hybrid DNAs (according to the manufacturer's instrucgene including intron/exon boundaries in 30 sporadic tions). By combining the data on chromosome 1p Généthon microsatellite markers previously run on the panel (accessed at the following breast tumors, 5 of which show loss of heterozygosity web site address: ftp://shgc.stanford.edu/pub/hgmc/RH_data/ at microsatellite markers in the region containing the rh_scores) and the data generated from this study, a common chro-MDGI gene.
mosomal region was identified. The region of common overlap suggested that MDGI was located centromeric to D1S233 and telomeric to MYCL1, as shown in Fig. 2 .
MATERIALS AND METHODS

Direct sequencing of the MDGI/FABP3 gene in sporadic tumors.
To sequence the gene, oligonucleotide primers were designed for Cloning and characterization of the human MDGI gene. A single flanking intron sequences for each exon, so as to include intron/exon cosmid clone (MDGI.3) containing the entire MDGI gene was isolated splice sites. Double-stranded DNA was PCR amplified for each exon, as described previously (Hung et al., 1995) . Sequencing of segments with the anti-sense primer 5-biotinylated. Each reaction consisted of this clone was performed using an ABI 373A automated sequencer of 35 cycles in a Perkin-Elmer 9600 thermocycler (Perkin-Elmer/ using the methodology of Chen et al. (1993) . The entire MDGI/FABP3 Cetus), employing the following temperatures and times: denaturgene was sequenced in addition to a few kilobases of the flanking ation, 94ЊC for 40 s; annealing, 58ЊC (exons 2, 3, and 4)/60ЊC (exon regions on both sides of the gene. The TED and autoTED programs 1) for 40 s; and elongation, 72ЊC for 40 s. The primer sequences and (Gleeson and Hiller, 1991) edited the primary DNA sequence data. sizes of amplified products for each exon are given in Table 3 . The Assembly of the data was performed using the XBAP program of PCR products were then purified by agarose gel electrophoresis, and the Staden package (Dear and Staden, 1991) . Alignments to known the band of appropriate size was excised from the gel. The DNA was sequences and further analysis of the sequence were performed using isolated from the gel by freeze/thawing (Phelan et al., 1995) , and the the GCG sequence analysis software (University of Wisconsin Genetbiotinylated DNA was bound to strepavidin beads (Dynabeads, Dynal ics Computer Group). The gene sequence revealed 100% identity with AS, Norway). Single-stranded DNA was then isolated by denaturing the previously published FABP3 cDNA. Intron/exon boundaries were the DNA with 0.2 M NaOH and separating the nonbiotinylated DNA determined by comparing the sequence of the FABP3 cDNA and strand from the biotinylated (attached to the beads) using a magnetic the cosmid clone (MDGI.3). The MDGI/FABP3 genomic sequence is rack (Magnetic Particle Concentrator, Dynal AS, Norway) (Phelan available in GenBank, and the structure is shown in Fig. 1 . . Both strands were sequenced using the Sanger dideoxy intron/exon border sequences are given in Table 1 , with exon sizes method with a USB Sequenase Version 2.0 kit. (USB, OH). The given in Table 2. sequencing reaction products were separated on 6% denaturing poly-Patient material. The 30 tumors in this study were obtained from acrylamide gels. Gels were transferred to filter paper (Whatman) surgery prior to irradiation and chemotherapy and immediately froand dried prior to exposure to Kodak XAR-5 film. zen at 070ЊC. Peripheral blood was also collected for each case.
Single-strand confirmation (SSC) analysis of sequence variants. Twenty-four cases were collected at the Karolinska Hospital, Stock-
To determine the frequency of the sequence variant in exon 2, SSC holm, Sweden and the remaining six cases at Duke University Medianalysis was developed for the exon 2 fragment. Genomic DNA (100 cal Centre, North Carolina, USA. DNA was isolated from the tumor ng) was amplified using the exon 2 primers ( et al., 1992) . Histopathological examination of tumor tissue was perand dGTP, 0.05 mM dATP, [a-35 S]dATP (Amersham) at 1 mCi/reacformed on tumor pieces adjacent to those studied, and classification tion, and 2 units of Taq DNA polymerase (BRL) in a final volume of was made according to the World Health Organization guidelines 12.5 ml. The reaction products were then diluted 1:3 with a stop buffer (Hutter, 1987) . Seventeen of the 30 tumors were ductal, 3 mucinous, (described above) and heated to 94ЊC for 10 min prior to loading on 3 medullary, 2 lobular, 2 papillary, 1 comedo, and 2 of unknown 6% nondenaturing polyacrylamide gels with/without 5% glycerol. histopathological subtype. The tumors were of malignancy stages I, The gels were run at 4ЊC for 4-6 h and then were dried at 80ЊC and II, or III, and the age of onset of breast cancer in the 30 women exposed to Kodak XAR-5 film. varied from 30 to 71 years.
Control population. The control population consisted of 90 Swedish individuals aged 50 and above who have shown no signs of breast
RESULTS
cancer.
Loss of heterozygosity analysis of 1p. The following polymorphic
The MDGI.3 cosmid clone that contains the gene (see microsatellite repeat markers from the 1p32-p35 region were typed on the constitutional and tumor DNA of the 30 sporadic breast cancer Materials and Methods) was sequenced, and alignment with the human FABP3 cDNA revealed 100% identity found in the breast tumors. A single novel sequence polymorphism was identified (Fig. 3) , which results in in the coding regions, implying that MDGI and FABP3 are the same gene. This gene consists of four exons the conversion of lysine to arginine in codon 53 (the amino acid positions are according to Peeters et al. (exon 1, 104 bp; exon 2, 173 bp; exon 3, 102 bp; exon 4, 284 bp) and three introns (intron 1, 3.38 kp; intron (1991) . This rare polymorphic variant is found in 1/30 women included in this study and in the constitutional 2, 1.89 kb; intron 3, 1.44 kb) spanning approximately 8 kb of genomic DNA (Fig. 1) . Exons 1 and 4 contain DNA of a further 3/26 women with sporadic breast cancer (data not shown). The variant was also detected in approximately 40 and 210 bp of 5-and 3-untranslated sequence, respectively. Each of the intron/exon bound-the constitutional DNA of 2/90 control individuals (P Å 0.20), who do not have breast cancer (Fig. 3) . aries was identified and sequenced (Table 1) to facilitate the search for mutations in the coding region and splice sites of the MDGI/FABP3 gene.
DISCUSSION
Six microsatellite repeat markers localized to chromosome 1p22-p35 ( Fig. 2) 
The MDGI/FABP3 gene has been demonstrated to have tumor suppressor activity in breast cancer in the interval where MDGI/FABP3 has been mapped by FISH) were evaluated for LOH in the constitutional following ways (Böhmer et al., 1987; Hung et al., 1995) .
(1) In vitro studies involving transfection of an MDGI-and tumor DNA of 30 breast cancer cases. Ten cases showed either complete or partial loss of this region expression construct into MCF-7 breast cancer cell lines resulted in reduced proliferative rates, altered (Fig. 2) . Two cases appear to have shown LOH of the entire region (cases D3 and 100), while the remaining morphology, and differentiation, compared to mocktransfected controls.
(2) Transfected breast cancer cell 8 cases showed partial losses involving both proximal portions (cases 8, 11, 36, 105, D177, and D176) and lines also showed a reduced ability to form tumors in nude mice compared to the untransfected controls distal portions (cases D27, D49, D176) of this interval. This observation is consistent with previously pub- (Hung et al., 1995) . (3) Immunostaining with an anti-FABP3 antibody revealed lack of expression of the pro-lished chromosome 1p microsatellite LOH data in breast cancer (Hoggard et al., 1995) . The localization tein in neoplastic breast cells compared to adjacent normal epithelia consistent with a role in breast tumor of the MDGI/FABP3 gene relative to the microsatellite repeat markers was determined using a PCR-based hy-development (Hung et al., 1995) . In addition, the treatment of mouse mammary epithelial cells with anti-brid panel (Research Genetics) (see Materials and Methods) . The gene appears to map between the loci sense MDGI phosphorothioate oligonucleotides resulted in an inhibition of DNA synthesis, suppression of markers D1S233 and MYCL1, where five of the tumors (D3, 100, D176, D27, and D49) show LOH. of alveolar budding, and impaired b-casein synthesis, suggesting a block in cell differentiation (Yang et al., In an attempt to identify mutations in the MDGI/ FABP3 gene in 30 sporadic breast tumors, the four 1994).
We have elucidated the complete sequence and geno-exons and flanking exon/intron junctions of this gene were sequenced (Tables 1 and 2) . No mutations were mic structure of the human MDGI/FABP3 gene (Fig. 1) so as to sequence all exons and their corresponding constitutional and tumor DNA of 5 breast tumors showing LOH in the MDGI region (Fig. 2) . In addition, we splice junctions to identify potential inactivating mutations in 30 sporadic breast cancers. The MDGI/FABP3 sequenced 25 tumors that appeared to show retention of this region. No mutations were found. The lack of gene has been previously localized by FISH to 1p32-p35 (Troxler et al., 1993; Hung et al., 1995) . We have gene mutation in these 30 breast tumors suggests that this is not a common mechanism of inactivation of more finely mapped the gene relative to 1p microsatellite markers in this region between D1S233 and MDGI/FABP3 in these neoplasms.
The rare exon 2 polymorphism was observed more MYCL1, consistent with the cytogenetic localization. This report and others have shown LOH in breast tu-frequently (4/56) in breast cancer cases than in controls (2/90) (P Å 0.20) (see Results). This missense amino mors in this region, suggesting that this chromosomal region may harbor tentative tumor suppressor genes. acid change (lysine to arginine) affects a highly conserved residue at codon 53 in one of the protein's two These studies have shown varying LOH frequencies ranging from 21 to 62% (Borg et al., 1992; Bieche et al., fatty-acid binding sites (Offner et al., 1988) . The significance of this observation is the subject of further 1993; Munn et al., 1995) and complicated patterns of allele loss (Hoggard et al., 1995) .
investigation. The detection of the rare polymorphism in exon 2 proved that our technique was sensitive and Tumor suppressor genes are thought to induce cancer by being inactivated, often by loss of one allele and efficient (Fig. 3) . Thus, we feel it is unlikely that small deletions and insertions or other single base substitu-mutation of the other (Knudson, 1993) . It is expected that tumors showing loss of the first allele (as shown tions would have escaped our detection. We also have analyzed 18 breast cancer cell lines for homozygous by LOH studies) are more likely to harbor point mutations in the second allele (Ruttledge et al., 1994) . Eluci-deletions of human MDGI/FABP3, using PCR amplification of exon 2 and an internal control from chromo-dation of the genomic structure of the human MDGI/ FABP3 gene allowed us to look for mutations in the some 22, but none were found (data not shown). Futreal, P., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., Bennett, L., Haugen-Strano, A., Swensen, J., Miki, Y., Eddington, K., McLure, M., Frye, C., Weaver-Feldhaus,
In conclusion, although transfection experiments J., Ding, W., Gholami, Z., Söderkvist, P., Terry, L., Jhanwar, S., Berchuck, A., Iglehart, J., Marks, J. D. G., Barrett, J., Skolnick, M., provide biological evidence for a suppressor activity of Kamb, A., and Wiseman, R. (1994) . BRCA1 mutations in primary MDGI/FABP3 in breast cancer, we did not observe breast and ovarian carcinomas. in sporadic breast cancers (Thompson et al., 1995) but Gleeson, R., and Hiller, L. (1991) . A trace display and editing program for data from fluorescence based sequencing machines. Nu-no point mutations have been found in 32 cases of spocleic Acids Res. 19: 6491-6493.
